Immunome, Inc.

Immunome, Inc.

IMNM·NASDAQ

$19.78

-0.15%
HealthcareBiotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.89B
EPS-2.4300
P/E Ratio-8.14
Earnings Date08/05/2026

imnm

Property, Plant, and Equipment (Net)

Last Annual Value

17.61M

3-Year CAGR

163%

5-Year CAGR

63%

10-Year CAGR

24%

Immunome, Inc.

Immunome, Inc. Competitors Analysis of Property, Plant, and Equipment (Net)

IMNM · NASDAQ
CompanyProperty, Plant, and Equipment (Net)
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
17.61M
69.2%83.1%N/A 
1.39M
11.0%N/AN/A
123.63M
-5.9%4.3%27.8%
2.37M
127.1%N/AN/A
25.16M
-10.4%N/AN/A
7.77M
5.4%3.6%-5.2%
1.92M
-14.2%N/AN/A
BHVN logo
Biohaven Ltd.
NYSE:BHVN
15.96M
-31.0%-2.0%N/A
0.00
N/AN/AN/A
Immunome, Inc.

Immunome, Inc. Fair Value Envelope

IMNM · NASDAQ

Our analysis suggests that IMNM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $19.78, this represents a potential HIDDEN relative to our calculated worth for Immunome, Inc..

Intrinsic Value
Current Price: $19.78